Data Quality KPIs for AI Workstreams


Published on 01/12/2025

Data Quality KPIs for AI Workstreams

Understanding AI/ML Model Validation

Artificial Intelligence (AI) and Machine Learning (ML) are fast becoming integral components in the pharmaceutical industry’s analytics practices, particularly in GxP environments. It is vital to ensure that AI/ML systems are validated effectively to meet the rigorous standards required by regulatory bodies like the FDA, EMA, and MHRA. This means not only validating the AI/ML models themselves but also ensuring that they are fit for their intended use and data readiness is discussed in detail.

Model validation involves several stages: the initial definition of intended use, data readiness curation, and assessing bias through rigorous testing methodologies such as bias and fairness testing. Beyond the basic checks, one must engage in continuous monitoring for potential drift, ensuring that models remain accurate and reliable over time.

Step 1: Defining Intended Use and Risk

The foundation of any AI/ML model validation process begins with a clear definition of its intended use. This comprises not merely the operational context but also the insights expected from model outputs. Let’s explore the steps needed for effective definition:

  • Identify Stakeholders: Collaborate with cross-functional teams including clinical operations, regulatory affairs, and data scientists to clarify what problems the model aims to address.
  • Document Expectations: Create a comprehensive scope document that outlines the specific outcomes anticipated from deploying the AI/ML model.
  • Risk Assessment: Utilize a risk-based approach to evaluate the potential impact of model outputs on patient safety, data integrity, and regulatory compliance.

Once the intended use has been defined, formal documentation becomes crucial. This aligns with regulatory standards such as 21 CFR Part 11 and GAMP 5, which emphasize the importance of thorough record-keeping and audit trails.

Step 2: Ensuring Data Readiness Curation

Data is the core of any AI/ML system, and its quality directly affects model performance. Here are the steps to ensure data readiness before model training:

  • Data Source Identification: Catalog all potential sources of data that will feed into the AI/ML model, ensuring they are valid, consistent, and reliable.
  • Data Quality Assessment: Implement checks to verify the accuracy, completeness, and timeliness of the collected data. Statistical methods and visualization techniques can be utilized here.
  • Bias Evaluation: Conduct an initial bias and fairness testing to identify any inherent biases in the data that could influence model outputs.

Different data sets can dramatically affect the reliability of AI/ML models. Therefore, ongoing monitoring is necessary to maintain the integrity of data and its readiness for model training.

Step 3: Model Verification and Validation (V&V)

Model V&V is a critical step in AI/ML workflows. It ensures not only that the models perform well but that they also comply with regulatory directives:

  • Verification: This involves checking if the model has been built correctly. Metrics such as accuracy, precision, and recall should be closely examined relative to predetermined thresholds established during the intended use phase.
  • Validation: Confirm that the model is fit for its intended purpose. This involves testing the model using independent datasets not used during training. The performance should meet the expectations laid out in the documentation.

To support these activities, you may employ tools for statistical validation and utilize frameworks like FDA’s” AI and ML guidelines to guide the V&V process.

Step 4: Implementing Explainability (XAI)

With the increasing complexity of AI/ML algorithms, explainability (XAI) has become a crucial factor in model validation. Stakeholders must readily understand how models make predictions to maintain trust and ensure regulatory compliance:

  • Adopting Explainability Tools: Use algorithms specifically designed for interpretability. Techniques such as LIME or SHAP help to elucidate model decisions, providing clarity and understanding.
  • Documentation: Keep comprehensive documentation of how explanations are generated and ensure they align with user requirements.
  • Stakeholder Training: Train end-users on how to interpret model outputs and the importance of explainability in a regulatory context.

Consider the ongoing dialogue with regulatory agencies regarding best practices in explainability, especially within frameworks such as the EMA’s guidelines on data integrity.

Step 5: Monitoring Drift and Re-validation

Once models are deployed, the process of validation does not cease. Continuous monitoring and testing are necessary to identify drift—changes in model performance over time:

  • Drift Monitoring: Implement systems to monitor key performance indicators (KPIs) and identify any discrepancies in real-time model outputs versus projected outcomes.
  • Triggers for Re-validation: Establish criteria that necessitate re-validation. These could include significant changes in data characteristics or when re-training is needed due to large shifts in incoming data.
  • Audit Trails: Maintain comprehensive logs of all model monitoring activities to support compliance and regulatory inquiries. Documentation of changes strengthens the validation case.

The process of drift monitoring and re-validation should be treated with utmost seriousness, especially when related to patient safety and data integrity.

Step 6: Ensuring AI Governance & Security

Governance strategies are imperative in navigating the regulatory landscape effectively. Comprehensive AI governance programs can further ensure that AI/ML outputs align with federal regulations:

  • Policy Development: Establishing clear policies that govern the development, deployment, and maintenance of AI systems is essential for compliance.
  • Data Security: Ensure that data handling practices are secure and auditable. This includes using encryption and secure access protocols to protect sensitive data.
  • Regular Audits: Conduct regular audits not just for data security, but also for compliance with AI governance policies to ensure adherence to prevailing regulations such as Annex 11.

Frameworks like the European Union’s General Data Protection Regulation (GDPR) should also inform governance and security practices, especially concerning data privacy.

Conclusion: The Path to Robust AI/ML Validation

As the pharmaceutical industry continues to embrace AI/ML technologies, the importance of rigorous validation practices cannot be overstated. By adhering to the structured approach detailed in this tutorial—defining intended use, ensuring data readiness, conducting thorough V&V, implementing explainability, monitoring for drift, and strengthening governance—pharma professionals can navigate the complexities of regulatory compliance while harnessing the full potential of AI/ML innovations in GxP analytics.

Ongoing education, collaboration, and adherence to scientific rigor will be paramount in successfully integrating AI/ML into pharmaceutical practices, ensuring that these systems remain not just cutting-edge, but also safe, effective, and compliant with regulatory benchmarks.